142 related articles for article (PubMed ID: 12153179)
1. Humoral immunodeficiency in chronic lymphocytic leukemia: role of CD95/CD95L in tumoral damage and escape.
Sampalo A; Brieva JA
Leuk Lymphoma; 2002 Apr; 43(4):881-4. PubMed ID: 12153179
[TBL] [Abstract][Full Text] [Related]
2. Chronic lymphocytic leukemia B cells inhibit spontaneous Ig production by autologous bone marrow cells: role of CD95-CD95L interaction.
Sampalo A; Navas G; Medina F; Segundo C; Cámara C; Brieva JA
Blood; 2000 Nov; 96(9):3168-74. PubMed ID: 11049999
[TBL] [Abstract][Full Text] [Related]
3. Clinical relevance of CD95 (Fas/Apo-1) on T cells of patients with B-cell chronic lymphocytic leukemia.
Groneberg C; Pickartz T; Binder A; Ringel F; Srock S; Sieber T; Schoeler D; Schriever F
Exp Hematol; 2003 Aug; 31(8):682-5. PubMed ID: 12901972
[TBL] [Abstract][Full Text] [Related]
4. Effects of preactivated autologous T lymphocytes on CD80, CD86 and CD95 expression by chronic lymphocytic leukemia B cells.
Romano C; De Fanis U; Sellitto A; Dalla Mora L; Chiurazzi F; Giunta R; Rotoli B; Lucivero G
Leuk Lymphoma; 2003 Nov; 44(11):1963-71. PubMed ID: 14738151
[TBL] [Abstract][Full Text] [Related]
5. Downregulation of the CD95 receptor and defect CD40-mediated signal transduction in B-chronic lymphocytic leukemia cells.
Laytragoon-Lewin N; Duhony E; Bai XF; Mellstedt H
Eur J Haematol; 1998 Oct; 61(4):266-71. PubMed ID: 9820634
[TBL] [Abstract][Full Text] [Related]
6. fas-mediated lysis of chronic lymphocytic leukaemia cells: role of type I versus type II cytokines and autologous fasL-expressing T cells.
Williams JF; Petrus MJ; Wright JA; Husebekk A; Fellowes V; Read EJ; Gress RE; Fowler DH
Br J Haematol; 1999 Oct; 107(1):99-105. PubMed ID: 10520029
[TBL] [Abstract][Full Text] [Related]
7. Tumor counterattack: fact or fiction?
Igney FH; Krammer PH
Cancer Immunol Immunother; 2005 Nov; 54(11):1127-36. PubMed ID: 15889255
[TBL] [Abstract][Full Text] [Related]
8. Activation-induced cell death: the controversial role of Fas and Fas ligand in immune privilege and tumour counterattack.
Maher S; Toomey D; Condron C; Bouchier-Hayes D
Immunol Cell Biol; 2002 Apr; 80(2):131-7. PubMed ID: 11940113
[TBL] [Abstract][Full Text] [Related]
9. Upstream mediators of the Fas apoptotic transduction pathway are defective in B-chronic lymphocytic leukemia.
Roué G; Lancry L; Duquesne F; Salaün V; Troussard X; Sola B
Leuk Res; 2001 Nov; 25(11):967-80. PubMed ID: 11597732
[TBL] [Abstract][Full Text] [Related]
10. Latent sensitivity to Fas-mediated apoptosis after CD40 ligation may explain activity of CD154 gene therapy in chronic lymphocytic leukemia.
Chu P; Deforce D; Pedersen IM; Kim Y; Kitada S; Reed JC; Kipps TJ
Proc Natl Acad Sci U S A; 2002 Mar; 99(6):3854-9. PubMed ID: 11891278
[TBL] [Abstract][Full Text] [Related]
11. Cell surface expression of CD25, CD54, and CD95 on B- and T-cells in chronic lymphocytic leukaemia in relation to trisomy 12, atypical morphology and clinical course.
Hjalmar V; Hast R; Kimby E
Eur J Haematol; 2002 Mar; 68(3):127-34. PubMed ID: 12068792
[TBL] [Abstract][Full Text] [Related]
12. On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model.
Greil R; Egle A; Villunger A
Leuk Lymphoma; 1998 Nov; 31(5-6):477-90. PubMed ID: 9922038
[TBL] [Abstract][Full Text] [Related]
13. The CD95(APO-1/Fas)/CD95L system.
Krammer PH
Toxicol Lett; 1998 Dec; 102-103():131-7. PubMed ID: 10022244
[TBL] [Abstract][Full Text] [Related]
14. Perturbation of the normal immune system in patients with CLL.
Forconi F; Moss P
Blood; 2015 Jul; 126(5):573-81. PubMed ID: 26084672
[TBL] [Abstract][Full Text] [Related]
15. Resistance to CD95-mediated apoptosis of CD40-activated chronic lymphocytic leukemia B cells is not related to lack of DISC molecules expression.
de Totero D; Montera M; Rosso O; Clavio M; Balleari E; Foa R; Gobbi M
Hematol J; 2004; 5(2):152-60. PubMed ID: 15048066
[TBL] [Abstract][Full Text] [Related]
16. The indispensable role of microenvironment in the natural history of low-grade B-cell neoplasms.
Ghia P; Caligaris-Cappio F
Adv Cancer Res; 2000; 79():157-73. PubMed ID: 10818680
[TBL] [Abstract][Full Text] [Related]
17. Quantitative characterization and potential function of membrane Fas/APO-1 (CD95) receptors on leukaemic cells from chronic B and T lymphoid leukaemias.
Kamihira S; Yamada Y; Hirakata Y; Tsuruda K; Sugahara K; Tomonaga M; Maeda T; Tsukasaki K; Atogami S; Kobayashi N
Br J Haematol; 1997 Dec; 99(4):858-65. PubMed ID: 9432034
[TBL] [Abstract][Full Text] [Related]
18. Expression of inhibitory receptor ILT3 on neoplastic B cells is associated with lymphoid tissue involvement in chronic lymphocytic leukemia.
Colovai AI; Tsao L; Wang S; Lin H; Wang C; Seki T; Fisher JG; Menes M; Bhagat G; Alobeid B; Suciu-Foca N
Cytometry B Clin Cytom; 2007 Sep; 72(5):354-62. PubMed ID: 17266150
[TBL] [Abstract][Full Text] [Related]
19. Study of CD40 ligand expression in B-cell chronic lymphocytic leukemia.
Brugnoni D; Rossi G; Tucci A; Cattaneo R; Airò P
Haematologica; 1995; 80(5):440-2. PubMed ID: 8566887
[TBL] [Abstract][Full Text] [Related]
20. CD40 stimulation of B-cell chronic lymphocytic leukaemia cells enhances the anti-apoptotic profile, but also Bid expression and cells remain susceptible to autologous cytotoxic T-lymphocyte attack.
Kater AP; Evers LM; Remmerswaal EB; Jaspers A; Oosterwijk MF; van Lier RA; van Oers MH; Eldering E
Br J Haematol; 2004 Nov; 127(4):404-15. PubMed ID: 15521917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
